Bruce Pynn is Oral Healths editorial board member for oral and maxillofacial surgery
This information will be valuable if you need to discuss concerns with your GP
The proportion of patients who achieved the HbA1c goal ranged from 25.9% (95% CI 18.534.9) with alpha -glucosidase inhibitors to 63.2% (54.171.5) with the long-acting GLP-1 analogue
The triple agonist mechanism targets complementary metabolic pathways simultaneously GLP-1 for appetite suppression and insulin secretion, GIP for enhanced incretin response, and glucagon for energy expenditure with the goal of achieving weight loss exceeding that seen with dual agonists such as tirzepatide
Most of the studies in fact, all the studies that we've seen now where we use patient-reported outcomes, meaning how's your physical functioning, in the trials they all go up across the board
Although not the most perfect scale, with many caveats, it is the most cost efficient evaluation, in addition to using waist circumference and waist-to-hip ratio
